PhoenixBio , Ltd. EBIT

As of the most recent data (June 2026), 6190.T shows a EBIT of $-19M. That compares with $-280M in the prior-year period — up 92.9% year over year. That is below the Healthcare sector average of $1.9T. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 6190.T's EBIT is now $-19M (was $-280M) — a 92.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether PhoenixBio , Ltd. is outperforming or lagging.

The Healthcare sector average EBIT is about $1.9T. PhoenixBio , Ltd. is at $-19M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how 6190.T stacks up against individual peers as well.

Tracking 6190.T's ebit over time shows whether PhoenixBio , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $-19M That compares with $-280M in the prior-year period — up 92.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has PhoenixBio , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-19M) with ownership activity and broader fundamentals.